首页 > 最新文献

International Journal of Nephrology and Renovascular Disease最新文献

英文 中文
Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye.
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-22 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S474716
Mustafa Arici, Saeed M G Al-Ghamdi, Alain G Assounga, Ahmed F El-Koraie, Abigail McMillan, Lucinda J Camidge, Budiwan Sumarsono, Martin Blogg, Daniel Bin Ng, Elvira P Lansang

Introduction: Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.

Methods: This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.

Results: Data were collected from 1788 patients and 217 physicians. A high proportion of patients had never received treatment for their anemia (n = 701, 39.2%); the most common treatment was erythropoietin-stimulating agents (ESAs) + intravenous iron (n = 457, 50.3%). High symptom burden was reported, with lack of energy being the most common symptom (n = 394, 75.6% treated and n = 133, 59.9% non-treated patients). Patients' self-reported symptom burden was higher than physician-reported burden; less agreement was seen for non-dialysis-dependent (NDD) patients (kappa = 0.193, standard deviation [SD]: 0.081) than dialysis-dependent (DD) patients (kappa = 0.442, SD: 0.103). Median hemoglobin thresholds that physicians reported using for initiating treatment (NDD: <10.5 [interquartile range, 9.5-12.0] g/dL; DD: <9.3 [9.0-10.0] g/dL) were higher than actual test levels at treatment initiation (NDD: 9.2 [8.7-10.0] g/dL; DD: 9.0 [8.1-10.0] g/dL).

Conclusion: Treatment inertia is apparent despite high symptom burden in the Middle East, South Africa, and Türkiye, and disagreement was seen in physician and patient perspectives on symptomology. Improved awareness of this disagreement may help facilitate physician-patient dialogue to improve patient experience.

{"title":"Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye.","authors":"Mustafa Arici, Saeed M G Al-Ghamdi, Alain G Assounga, Ahmed F El-Koraie, Abigail McMillan, Lucinda J Camidge, Budiwan Sumarsono, Martin Blogg, Daniel Bin Ng, Elvira P Lansang","doi":"10.2147/IJNRD.S474716","DOIUrl":"10.2147/IJNRD.S474716","url":null,"abstract":"<p><strong>Introduction: </strong>Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.</p><p><strong>Methods: </strong>This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.</p><p><strong>Results: </strong>Data were collected from 1788 patients and 217 physicians. A high proportion of patients had never received treatment for their anemia (n = 701, 39.2%); the most common treatment was erythropoietin-stimulating agents (ESAs) + intravenous iron (n = 457, 50.3%). High symptom burden was reported, with lack of energy being the most common symptom (n = 394, 75.6% treated and n = 133, 59.9% non-treated patients). Patients' self-reported symptom burden was higher than physician-reported burden; less agreement was seen for non-dialysis-dependent (NDD) patients (kappa = 0.193, standard deviation [SD]: 0.081) than dialysis-dependent (DD) patients (kappa = 0.442, SD: 0.103). Median hemoglobin thresholds that physicians reported using for initiating treatment (NDD: <10.5 [interquartile range, 9.5-12.0] g/dL; DD: <9.3 [9.0-10.0] g/dL) were higher than actual test levels at treatment initiation (NDD: 9.2 [8.7-10.0] g/dL; DD: 9.0 [8.1-10.0] g/dL).</p><p><strong>Conclusion: </strong>Treatment inertia is apparent despite high symptom burden in the Middle East, South Africa, and Türkiye, and disagreement was seen in physician and patient perspectives on symptomology. Improved awareness of this disagreement may help facilitate physician-patient dialogue to improve patient experience.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"27-42"},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11766225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation Between the Inferior Vena Cava/Aorta (Ivc/Ao) Ratio and Serum Lactate Levels in Children With Renal Disorder.
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-22 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S488639
Dzulfikar Djalil Lukmanul Hakim, Ahmedz Widiasta, Dedi Rachmadi, Sri Endah Rahayunigsih, Putria Rayani Apandi, Riyadi Adrizain, Muhamad Rinaldhi Akbar Martiano

Background: Acute kidney injury (AKI) is common in critically ill children in the PICU, with incidence rates from 2.5% to 58%, impacting mortality and hospital duration. Early AKI detection is vital, but conventional hemodynamic monitoring often lacks specificity. This study investigates the relationship between the inferior vena cava/aortic (IVC/Ao) ratio and serum lactate levels as non-invasive indicators of renal hemodynamics and tissue perfusion in children. Understanding these parameters could improve early diagnosis, aid clinical decisions, and enhance outcomes for pediatric AKI patients, offering an accessible monitoring method for clinicians.

Methods: This cross-sectional study involved 48 pediatric patients aged 5-18 years showing Pediatric Early Warning Score (PEWS) ≥3 and diagnosed with renal disorders. Patients were admitted to the emergency department, high care unit, PICU, and pediatric ward at Dr. Hasan Sadikin Hospital, Bandung, between May and August 2023. AKI was diagnosed using pRIFLE or KDIGO criteria. The IVC/Ao ratio was assessed via transabdominal USG, and serum lactate levels were measured. Spearman correlation analysis was conducted to assess their relationship.

Results: The median (IQR) IVC/Ao ratio was 0.91 (0.70-1.10), and serum lactate levels were 1.5 (1.1-2.4) mmol/L. Spearman correlation analysis revealed a negative correlation between the IVC/Ao ratio and serum lactate (rho = -0.65, p < 0.001).

Conclusion: A decrease in the IVC/Ao ratio correlates with an increase in serum lactate levels in children with AKI.

{"title":"Correlation Between the Inferior Vena Cava/Aorta (Ivc/Ao) Ratio and Serum Lactate Levels in Children With Renal Disorder.","authors":"Dzulfikar Djalil Lukmanul Hakim, Ahmedz Widiasta, Dedi Rachmadi, Sri Endah Rahayunigsih, Putria Rayani Apandi, Riyadi Adrizain, Muhamad Rinaldhi Akbar Martiano","doi":"10.2147/IJNRD.S488639","DOIUrl":"10.2147/IJNRD.S488639","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is common in critically ill children in the PICU, with incidence rates from 2.5% to 58%, impacting mortality and hospital duration. Early AKI detection is vital, but conventional hemodynamic monitoring often lacks specificity. This study investigates the relationship between the inferior vena cava/aortic (IVC/Ao) ratio and serum lactate levels as non-invasive indicators of renal hemodynamics and tissue perfusion in children. Understanding these parameters could improve early diagnosis, aid clinical decisions, and enhance outcomes for pediatric AKI patients, offering an accessible monitoring method for clinicians.</p><p><strong>Methods: </strong>This cross-sectional study involved 48 pediatric patients aged 5-18 years showing Pediatric Early Warning Score (PEWS) ≥3 and diagnosed with renal disorders. Patients were admitted to the emergency department, high care unit, PICU, and pediatric ward at Dr. Hasan Sadikin Hospital, Bandung, between May and August 2023. AKI was diagnosed using pRIFLE or KDIGO criteria. The IVC/Ao ratio was assessed via transabdominal USG, and serum lactate levels were measured. Spearman correlation analysis was conducted to assess their relationship.</p><p><strong>Results: </strong>The median (IQR) IVC/Ao ratio was 0.91 (0.70-1.10), and serum lactate levels were 1.5 (1.1-2.4) mmol/L. Spearman correlation analysis revealed a negative correlation between the IVC/Ao ratio and serum lactate (rho = -0.65, p < 0.001).</p><p><strong>Conclusion: </strong>A decrease in the IVC/Ao ratio correlates with an increase in serum lactate levels in children with AKI.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"43-51"},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11766292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial Toxicity and Kidney Disease in Children and Adults: A Scoping Review.
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-21 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S485111
Rossella Siligato, Guido Gembillo, Alfredo De Giorgi, Alessio Di Maria, Laura Maria Scichilone, Matteo Capone, Francesca Maria Vinci, Simone Nicoletti, Marta Bondanelli, Cristina Malaventura, Alda Storari, Domenico Santoro, Sara Dionisi, Fabio Fabbian

Purpose: Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This scoping review aimed to evaluate the literature linking FT with renal diseases.

Patients and methods: We Included all studies analyzing FT and renal disease recorded in PubMed, Embase and Google Scholar between 2013 and 2023. The research question was formulated with reference to the acronym PCC (Problem, Concept and Contest). For each included study, we considered the study design, the population and main results from different populations with distinct renal conditions and the results were summarized in four tables.

Results: Socioeconomic deprivation was the main cause of FT, and the majority of studies on the relationship between FT and chronic kidney disease (CKD) were conducted in the USA (4 studies evaluated the pediatric population and 6 studies included adults). Three studies reported the impact of FT on nephrolithiasis, and 3 studies analyzed the link between FT and renal tumors. The methods used for detecting FT differed and were based on consultations, questionnaires, expenditures and database records analysis. The COmprehensive Score for financial Toxicity (COST) questionnaire was used in 7 studies (43%), and the prevalence of FT was reported to be high in children and adults.

Conclusion: Although the quality of the selected study is limited, due to different populations investigated and heterogeneity in detecting FT, the latter seems to be a frequent finding in people with renal disease. Health care professionals should recognize socioeconomic deprivation as the major cause of FT. Detecting FT could help in prioritizing patient-centered care in populations with renal diseases through the development of strategies aimed at improving care for people with kidney diseases.

{"title":"Financial Toxicity and Kidney Disease in Children and Adults: A Scoping Review.","authors":"Rossella Siligato, Guido Gembillo, Alfredo De Giorgi, Alessio Di Maria, Laura Maria Scichilone, Matteo Capone, Francesca Maria Vinci, Simone Nicoletti, Marta Bondanelli, Cristina Malaventura, Alda Storari, Domenico Santoro, Sara Dionisi, Fabio Fabbian","doi":"10.2147/IJNRD.S485111","DOIUrl":"https://doi.org/10.2147/IJNRD.S485111","url":null,"abstract":"<p><strong>Purpose: </strong>Social determinants of health have been related with kidney diseases and their outcomes. Financial toxicity (FT) refers to the negative impact of health care costs on clinical conditions. This scoping review aimed to evaluate the literature linking FT with renal diseases.</p><p><strong>Patients and methods: </strong>We Included all studies analyzing FT and renal disease recorded in PubMed, Embase and Google Scholar between 2013 and 2023. The research question was formulated with reference to the acronym PCC (Problem, Concept and Contest). For each included study, we considered the study design, the population and main results from different populations with distinct renal conditions and the results were summarized in four tables.</p><p><strong>Results: </strong>Socioeconomic deprivation was the main cause of FT, and the majority of studies on the relationship between FT and chronic kidney disease (CKD) were conducted in the USA (4 studies evaluated the pediatric population and 6 studies included adults). Three studies reported the impact of FT on nephrolithiasis, and 3 studies analyzed the link between FT and renal tumors. The methods used for detecting FT differed and were based on consultations, questionnaires, expenditures and database records analysis. The COmprehensive Score for financial Toxicity (COST) questionnaire was used in 7 studies (43%), and the prevalence of FT was reported to be high in children and adults.</p><p><strong>Conclusion: </strong>Although the quality of the selected study is limited, due to different populations investigated and heterogeneity in detecting FT, the latter seems to be a frequent finding in people with renal disease. Health care professionals should recognize socioeconomic deprivation as the major cause of FT. Detecting FT could help in prioritizing patient-centered care in populations with renal diseases through the development of strategies aimed at improving care for people with kidney diseases.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"13-25"},"PeriodicalIF":2.1,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Insights on Childhood Lupus Nephritis. 儿童狼疮性肾炎的新认识。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.2147/IJNRD.S405789
Rodrigo Marchi-Silva, Bruna Martins De Aquino, Ana Carolina Londe, Taίs Nitsch Mazzola, Paulo Rogério Julio, Theresa Wampler Muskardin, Simone Appenzeller

Approximately one in five patients with systemic lupus erythematosus (SLE) has disease-onset during childhood (cSLE). Lupus nephritis is more common in cSLE than adult-onset SLE and is associated with significant and increased morbidity and mortality. In this article, we review lupus nephritis in cSLE, including pathogenesis, diagnosis, biomarkers, and management through PUBMED search between July and December 2024. Diagnosis of lupus nephritis is made in 93% of cSLE patients during the first 2 years of disease. The majority of patients have active disease in other organs, and nephrotic range proteinuria and hypertension is frequently observed at diagnosis. Class III and IV are observed in over 50% of renal biopsies and progression to end-stage renal disease varies across cohorts. Major progress made in recent years includes adjustment of the proportion of fibrous crescents when scoring nephritis in cSLE to better discriminate kidney disease outcomes, and development of non-invasive biomarkers to identify renal disease activity and damage. It is anticipated that accurate non-invasive biomarkers will foster multicenter studies and help identify new treatment approaches to improve outcomes in cSLE nephritis.

大约五分之一的系统性红斑狼疮(SLE)患者在儿童期发病(cSLE)。狼疮性肾炎在cSLE中比成人SLE更常见,并且与显著增加的发病率和死亡率相关。在这篇文章中,我们回顾了狼疮性肾炎在cSLE,包括发病机制,诊断,生物标志物,和管理通过PUBMED检索在2024年7月至12月。狼疮性肾炎的诊断在93%的cSLE患者在疾病的头2年。大多数患者在其他器官有活动性疾病,诊断时常观察到肾病范围、蛋白尿和高血压。III类和IV类在超过50%的肾活检中被观察到,并且在不同队列中进展到终末期肾脏疾病有所不同。近年来取得的主要进展包括:调整纤维月牙在评价cSLE肾炎时的比例,以更好地区分肾脏疾病的预后,以及开发非侵入性生物标志物来识别肾脏疾病的活动性和损害。预计准确的非侵入性生物标志物将促进多中心研究,并帮助确定新的治疗方法来改善cSLE肾炎的预后。
{"title":"New Insights on Childhood Lupus Nephritis.","authors":"Rodrigo Marchi-Silva, Bruna Martins De Aquino, Ana Carolina Londe, Taίs Nitsch Mazzola, Paulo Rogério Julio, Theresa Wampler Muskardin, Simone Appenzeller","doi":"10.2147/IJNRD.S405789","DOIUrl":"https://doi.org/10.2147/IJNRD.S405789","url":null,"abstract":"<p><p>Approximately one in five patients with systemic lupus erythematosus (SLE) has disease-onset during childhood (cSLE). Lupus nephritis is more common in cSLE than adult-onset SLE and is associated with significant and increased morbidity and mortality. In this article, we review lupus nephritis in cSLE, including pathogenesis, diagnosis, biomarkers, and management through PUBMED search between July and December 2024. Diagnosis of lupus nephritis is made in 93% of cSLE patients during the first 2 years of disease. The majority of patients have active disease in other organs, and nephrotic range proteinuria and hypertension is frequently observed at diagnosis. Class III and IV are observed in over 50% of renal biopsies and progression to end-stage renal disease varies across cohorts. Major progress made in recent years includes adjustment of the proportion of fibrous crescents when scoring nephritis in cSLE to better discriminate kidney disease outcomes, and development of non-invasive biomarkers to identify renal disease activity and damage. It is anticipated that accurate non-invasive biomarkers will foster multicenter studies and help identify new treatment approaches to improve outcomes in cSLE nephritis.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification and Management of CKD-Associated Pruritus: Current Insights. ckd相关瘙痒的识别和管理:当前的见解。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-28 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S499798
Tomasz Skrzypczak, Anna Skrzypczak, Piotr Nockowski, Jacek C Szepietowski

Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers. This is likely due to uncertainty regarding its diagnosis and treatment. Most commonly, CKD-aP could be screened with questionnaires like the KDQoL-36 and WI-NRS, chosen for their simplicity and ease of use. Prior treatment studies of CKD-aP were mostly limited by noncontrolled design and small sample size. First CKD-aP medication - difelikefalin a powerful, new therapeutic option was approved by Federal Drug Administration (FDA) in 2021 and European Medicines Agency (EMA) in 2022. Recent expert opinions, clinical trials and metanalysis identified difelikefalin and gabapentinoids as medications of choice in treatment of CKD-aP. All these findings improved current understanding and management of this condition.

慢性肾脏疾病相关性瘙痒(CKD- ap)是慢性肾脏疾病(CKD)和终末期肾脏疾病患者的常见和令人痛苦的问题。它影响了大约20%的CKD患者和40%的终末期肾病患者。尽管它与较差的社会心理和医疗结果明显相关,但它往往被患者低估,并且经常被医疗保健提供者忽视。这可能是由于其诊断和治疗的不确定性。最常见的是,CKD-aP可以通过像KDQoL-36和WI-NRS这样的问卷进行筛查,选择这些问卷是因为它们简单易用。先前CKD-aP的治疗研究大多受到非对照设计和小样本量的限制。首个CKD-aP药物- difelikefalin是一种强大的新治疗选择,于2021年获得美国联邦药物管理局(FDA)批准,并于2022年获得欧洲药品管理局(EMA)批准。最近的专家意见、临床试验和荟萃分析确定异花铁素和加巴喷丁类药物是治疗CKD-aP的首选药物。所有这些发现都改善了目前对这种疾病的理解和管理。
{"title":"Identification and Management of CKD-Associated Pruritus: Current Insights.","authors":"Tomasz Skrzypczak, Anna Skrzypczak, Piotr Nockowski, Jacek C Szepietowski","doi":"10.2147/IJNRD.S499798","DOIUrl":"10.2147/IJNRD.S499798","url":null,"abstract":"<p><p>Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers. This is likely due to uncertainty regarding its diagnosis and treatment. Most commonly, CKD-aP could be screened with questionnaires like the KDQoL-36 and WI-NRS, chosen for their simplicity and ease of use. Prior treatment studies of CKD-aP were mostly limited by noncontrolled design and small sample size. First CKD-aP medication - difelikefalin a powerful, new therapeutic option was approved by Federal Drug Administration (FDA) in 2021 and European Medicines Agency (EMA) in 2022. Recent expert opinions, clinical trials and metanalysis identified difelikefalin and gabapentinoids as medications of choice in treatment of CKD-aP. All these findings improved current understanding and management of this condition.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"339-354"},"PeriodicalIF":2.1,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Acute Lobar Nephronia: A Case Series and Literature Review. 儿童急性大叶性肾病:病例系列及文献回顾。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-17 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S491182
Kfir Lavi, Adi Klein, Noy Shtein, Vered Schichter Konfino, Vered Nir

Introduction: Acute lobar nephronia (ALN) is a focal renal infection without liquefaction, historically regarded as rare in the pediatric population, yet recent literature suggests it may be under-diagnosed, which may result in the formation of renal abscess and future renal scarring.

Methods: The clinical presentation, investigations, treatment and long-term outcomes of 5 patients diagnosed with ALN was described and literature review was conducted by reviewing publications in PubMed using the keywords "acute lobar nephronia" and "pediatric".

Results: Three patients were males, aged 1 to 11 years. The primary complaint in all cases was fever, accompanied by significantly elevated inflammatory markers. Upon presentation, none of the patients exhibited pyuria on urinalysis, and all had sterile blood and urine cultures. Diagnosis was based on CT scans for three patients and renal sonography for two. Main findings included hyperechogenic renal parenchyma, and hypodense localized parenchyma. Treatment consisted of broad-spectrum intravenous antibiotics, administered for 7 to 12 days and additional 1 week course with amoxicillin-clavulanate, resulting in similar defervescence times across all patients. None of the patients demonstrated recurrence and none had renal pathology upon repeated renal sonography and upon DMSA scintigraphy.

Discussion: Clinical suspicion for ALN should arise in cases of abdominal pain and markedly increased inflammatory markers. It"s crucial to note that the absence of pyuria and negative culture results should not exclude ALN diagnosis, underscoring the need for a high index of suspicion in the pediatric population.

简介:急性大叶性肾病(ALN)是一种没有液化的局灶性肾脏感染,历来被认为在儿科人群中罕见,但最近的文献表明,它可能被诊断不足,这可能导致肾脓肿的形成和未来的肾瘢痕。方法:以“急性大叶性肾病”和“儿科”为关键词,对5例ALN患者的临床表现、调查、治疗及远期预后进行分析,并对PubMed上发表的文献进行复习。结果:男性3例,年龄1 ~ 11岁。所有病例的主要主诉均为发热,并伴有炎症标志物显著升高。在就诊时,没有患者在尿液分析中表现出脓尿,所有患者都有无菌血和尿培养。三名患者的诊断是基于CT扫描,两名患者的肾脏超声检查。主要表现为肾实质高回声,局限性实质低密度。治疗包括广谱静脉注射抗生素,给药7 - 12天,另外用阿莫西林-克拉维酸治疗1周,所有患者的退热时间相似。经反复肾超声检查和DMSA显像检查均无复发,无肾脏病变。讨论:在腹痛和炎症标志物明显增加的情况下,临床应怀疑ALN。重要的是要注意,没有脓尿和阴性培养结果不应排除ALN的诊断,强调在儿科人群中需要高度怀疑。
{"title":"Pediatric Acute Lobar Nephronia: A Case Series and Literature Review.","authors":"Kfir Lavi, Adi Klein, Noy Shtein, Vered Schichter Konfino, Vered Nir","doi":"10.2147/IJNRD.S491182","DOIUrl":"10.2147/IJNRD.S491182","url":null,"abstract":"<p><strong>Introduction: </strong>Acute lobar nephronia (ALN) is a focal renal infection without liquefaction, historically regarded as rare in the pediatric population, yet recent literature suggests it may be under-diagnosed, which may result in the formation of renal abscess and future renal scarring.</p><p><strong>Methods: </strong>The clinical presentation, investigations, treatment and long-term outcomes of 5 patients diagnosed with ALN was described and literature review was conducted by reviewing publications in PubMed using the keywords \"acute lobar nephronia\" and \"pediatric\".</p><p><strong>Results: </strong>Three patients were males, aged 1 to 11 years. The primary complaint in all cases was fever, accompanied by significantly elevated inflammatory markers. Upon presentation, none of the patients exhibited pyuria on urinalysis, and all had sterile blood and urine cultures. Diagnosis was based on CT scans for three patients and renal sonography for two. Main findings included hyperechogenic renal parenchyma, and hypodense localized parenchyma. Treatment consisted of broad-spectrum intravenous antibiotics, administered for 7 to 12 days and additional 1 week course with amoxicillin-clavulanate, resulting in similar defervescence times across all patients. None of the patients demonstrated recurrence and none had renal pathology upon repeated renal sonography and upon DMSA scintigraphy.</p><p><strong>Discussion: </strong>Clinical suspicion for ALN should arise in cases of abdominal pain and markedly increased inflammatory markers. It\"s crucial to note that the absence of pyuria and negative culture results should not exclude ALN diagnosis, underscoring the need for a high index of suspicion in the pediatric population.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"333-337"},"PeriodicalIF":2.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal Relationships Between Gut Microbiota, Metabolites, and Diabetic Nephropathy: Insights from a Two-Sample Mendelian Randomization Analysis. 肠道菌群、代谢物和糖尿病肾病之间的因果关系:来自两样本孟德尔随机化分析的见解。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-10 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S489074
Xixi Song, Jingqiu Cui, Shiwei Li, Bo Huang

Background:  Previous studies have established a correlation between gut microbiota, metabolites, and diabetic nephropathy (DN). However, the inherent limitations of observational studies, including reverse causality and confounding factors, made this relationship uncertain.

Methods: In this study, we compiled summary statistics from a genome-wide association study (GWAS) conducted on gut microbiota, metabolites, and DN. We employed a two-sample Mendelian randomization (MR) approach, utilizing inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode methods.

Results:  We detected the protective nature of genetically predicted representatives from the family Bacteroidaceae (OR: 0.716, 95% CI: 0.516-0.995, p = 0.046), family Victivallaceae (OR: 0.871, 95% CI: 0.772-0.982, p = 0.026), genus Bacteroides (OR: 0.716, 95% CI: 0.516-0.995, p = 0.046), genus Coprococcus 2 (OR: 0.745, 95% CI: 0.576-0.963, p = 0.025), and genus Lactococcus (OR: 0.851, 95% CI: 0.730-0.992, p = 0.039) against the development of DN. Conversely, we identified a positive correlation between the incidence of DN and entities, such as Phylum Bacteroidetes (OR: 1.427, 95% CI: 1.085-1.875, p = 0.011), class Bacteroidia (OR: 1.304, 95% CI: 1.036-1.641,p = 0.024), order Bacteroidales (OR: 1.304, 95% CI: 1.035-1.641, p = 0.028), genus Catenibacterium (OR: 1.312, 95% CI: 1.079-1.594, p = 0.006), genus Lachnoclostridium (OR: 1.434, 95% CI: 1.129-1.821, p = 0.003), and genus Parasutterella (OR: 1.270, 95% CI: 1.070-1.510, p = 0.006). In our analysis, none of the gut metabolites demonstrated a causal relationship with DN.

Conclusion:  Our results substantiated the potential causal association between specific gut microbiota and DN. Therefore, our study offers novel insight into the mechanisms underlying DN. This finding provides a theoretical foundation for the future development of targeted strategies for the prevention and treatment of DN.

背景: 以往的研究已证实肠道微生物群、代谢物和糖尿病肾病(DN)之间存在相关性。然而,观察性研究固有的局限性,包括反向因果关系和混杂因素,使得这种关系并不确定:在本研究中,我们汇编了一项关于肠道微生物群、代谢物和糖尿病肾病的全基因组关联研究(GWAS)的统计摘要。我们采用了双样本孟德尔随机化(Mendelian randomization,MR)方法,利用了反方差加权(IVW)、MR-Egger、加权中位数和加权模式等方法: 我们检测到细菌科(OR:0.716,95% CI:0.516-0.995,p = 0.046)、Victivallaceae 科(OR:0.871,95% CI:0.772-0.982,p = 0.OR:0.716,95% CI:0.516-0.995,p = 0.046)、Coprococcus 2 属(OR:0.745,95% CI:0.576-0.963,p = 0.025)和乳球菌属(OR:0.851,95% CI:0.730-0.992,p = 0.039)与 DN 的发生呈正相关。相反,我们发现 DN 的发病率与实体呈正相关,如细菌门(OR:1.427,95% CI:1.085-1.875,p = 0.011)、类杆菌科(OR:1.304,95% CI:1.036-1.641,p = 0.024)、类杆菌目(OR:1.304,95% CI:1.035-1.641,p = 0.028)、卡氏菌属(OR:1.312,95% CI:1.079-1.594,p = 0.006)、拉氏菌属(OR:1.434,95% CI:1.129-1.821,p = 0.003)和副菌属(OR:1.270,95% CI:1.070-1.510,p = 0.006)。在我们的分析中,没有一种肠道代谢物与 DN 有因果关系: 我们的研究结果证实了特定肠道微生物群与 DN 之间的潜在因果关系。因此,我们的研究为了解 DN 的内在机制提供了新的视角。这一发现为今后制定有针对性的预防和治疗 DN 的策略提供了理论基础。
{"title":"Causal Relationships Between Gut Microbiota, Metabolites, and Diabetic Nephropathy: Insights from a Two-Sample Mendelian Randomization Analysis.","authors":"Xixi Song, Jingqiu Cui, Shiwei Li, Bo Huang","doi":"10.2147/IJNRD.S489074","DOIUrl":"10.2147/IJNRD.S489074","url":null,"abstract":"<p><strong>Background: </strong> Previous studies have established a correlation between gut microbiota, metabolites, and diabetic nephropathy (DN). However, the inherent limitations of observational studies, including reverse causality and confounding factors, made this relationship uncertain.</p><p><strong>Methods: </strong>In this study, we compiled summary statistics from a genome-wide association study (GWAS) conducted on gut microbiota, metabolites, and DN. We employed a two-sample Mendelian randomization (MR) approach, utilizing inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode methods.</p><p><strong>Results: </strong> We detected the protective nature of genetically predicted representatives from the family Bacteroidaceae (OR: 0.716, 95% CI: 0.516-0.995, <i>p</i> = 0.046), family Victivallaceae (OR: 0.871, 95% CI: 0.772-0.982, <i>p</i> = 0.026), genus Bacteroides (OR: 0.716, 95% CI: 0.516-0.995, <i>p</i> = 0.046), genus Coprococcus 2 (OR: 0.745, 95% CI: 0.576-0.963, <i>p</i> = 0.025), and genus Lactococcus (OR: 0.851, 95% CI: 0.730-0.992, <i>p</i> = 0.039) against the development of DN. Conversely, we identified a positive correlation between the incidence of DN and entities, such as Phylum Bacteroidetes (OR: 1.427, 95% CI: 1.085-1.875, <i>p</i> = 0.011), class Bacteroidia (OR: 1.304, 95% CI: 1.036-1.641,<i>p</i> = 0.024), order Bacteroidales (OR: 1.304, 95% CI: 1.035-1.641, <i>p</i> = 0.028), genus Catenibacterium (OR: 1.312, 95% CI: 1.079-1.594, <i>p</i> = 0.006), genus Lachnoclostridium (OR: 1.434, 95% CI: 1.129-1.821, <i>p</i> = 0.003), and genus Parasutterella (OR: 1.270, 95% CI: 1.070-1.510, <i>p</i> = 0.006). In our analysis, none of the gut metabolites demonstrated a causal relationship with DN.</p><p><strong>Conclusion: </strong> Our results substantiated the potential causal association between specific gut microbiota and DN. Therefore, our study offers novel insight into the mechanisms underlying DN. This finding provides a theoretical foundation for the future development of targeted strategies for the prevention and treatment of DN.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"319-332"},"PeriodicalIF":2.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of Shear Wave Elastography in the Evaluation of Chronic Kidney Disease. 横波弹性成像在慢性肾脏疾病诊断中的价值。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-06 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S480501
Shivarajkumar K Lakshmana, Prakashini Koteshwar, Tanushree Kamath

Purpose and motivation: Chronic kidney disease (CKD) is a major global public health problem with eventual progression to end-stage renal disease which tends to increase kidney stiffness. Shear wave elastography (SWE) is a recently developed ultrasound based technique which can be used to assess tissue stiffness noninvasively. The aim of this study was to evaluate the potential diagnostic value of SWE to assess renal parenchymal stiffness in CKD and its correlation with estimated glomerular filtration rate (eGFR), which may be used as a marker for detecting and staging CKD.

Materials and methods: The study protocol was approved by the Institutional ethics Committee at Kasturba medical college, Manipal and written informed consent was obtained from all participants. The study included 93 control subjects and 108 patients with CKD. SWE imaging was performed to assess renal cortical stiffness, as measured by the Young's modulus (YM). Correlations between SWE and conventional ultrasound parameters with age, serum creatinine, eGFR and serum urea were analysed using Pearson's correlation coefficient (p ≤ 0.05) and receiver operating characteristic (ROC) curves were derived.

Results: The diagnostic performance of SWE correlated with serum creatinine levels and eGFR. We found a statistically significant difference in kidney stiffness values between healthy individuals and CKD patients. The Spearman correlation coefficient revealed moderate negative linear correlation between the YM measurements and eGFR. We obtained a YM measurement cut-off value of 4.43 kPa, a value less than or equal to this suggested a no diseased kidney. This yielded sensitivity and specificity of 92.6% and 80.6%, respectively, with an AUROC of 0.92.

Conclusion: Our results demonstrated that shear wave elastography may provide a low-cost, non-invasive method for the morphological assessment and progression of the disease status in chronic kidney disease patients with CKD.

目的和动机:慢性肾脏疾病(CKD)是一个主要的全球公共卫生问题,最终发展为终末期肾脏疾病,往往会增加肾脏僵硬。横波弹性成像(SWE)是近年来发展起来的一种基于超声的技术,可用于无创评估组织刚度。本研究的目的是评估SWE在CKD中评估肾实质硬度的潜在诊断价值及其与肾小球滤过率(eGFR)的相关性,eGFR可能被用作CKD检测和分期的标志。材料和方法:研究方案经马尼帕尔Kasturba医学院机构伦理委员会批准,并获得所有参与者的书面知情同意。该研究包括93名对照组和108名CKD患者。SWE成像通过杨氏模量(YM)来评估肾皮质硬度。采用Pearson相关系数(p≤0.05)分析SWE与常规超声参数与年龄、血清肌酐、eGFR、血清尿素的相关性,并推导受试者工作特征(ROC)曲线。结果:SWE的诊断价值与血清肌酐水平和eGFR相关。我们发现健康个体和CKD患者的肾硬度值有统计学上的显著差异。Spearman相关系数显示YM测量值与eGFR之间存在中度负线性相关。我们得到的YM测量临界值为4.43 kPa,小于或等于这个值表明肾脏没有病变。该方法的敏感性和特异性分别为92.6%和80.6%,AUROC为0.92。结论:横波弹性成像可为慢性肾脏疾病合并CKD患者提供一种低成本、无创的形态学评估和疾病进展的方法。
{"title":"Value of Shear Wave Elastography in the Evaluation of Chronic Kidney Disease.","authors":"Shivarajkumar K Lakshmana, Prakashini Koteshwar, Tanushree Kamath","doi":"10.2147/IJNRD.S480501","DOIUrl":"10.2147/IJNRD.S480501","url":null,"abstract":"<p><strong>Purpose and motivation: </strong>Chronic kidney disease (CKD) is a major global public health problem with eventual progression to end-stage renal disease which tends to increase kidney stiffness. Shear wave elastography (SWE) is a recently developed ultrasound based technique which can be used to assess tissue stiffness noninvasively. The aim of this study was to evaluate the potential diagnostic value of SWE to assess renal parenchymal stiffness in CKD and its correlation with estimated glomerular filtration rate (eGFR), which may be used as a marker for detecting and staging CKD.</p><p><strong>Materials and methods: </strong>The study protocol was approved by the Institutional ethics Committee at Kasturba medical college, Manipal and written informed consent was obtained from all participants. The study included 93 control subjects and 108 patients with CKD. SWE imaging was performed to assess renal cortical stiffness, as measured by the Young's modulus (YM). Correlations between SWE and conventional ultrasound parameters with age, serum creatinine, eGFR and serum urea were analysed using Pearson's correlation coefficient (p ≤ 0.05) and receiver operating characteristic (ROC) curves were derived.</p><p><strong>Results: </strong>The diagnostic performance of SWE correlated with serum creatinine levels and eGFR. We found a statistically significant difference in kidney stiffness values between healthy individuals and CKD patients. The Spearman correlation coefficient revealed moderate negative linear correlation between the YM measurements and eGFR. We obtained a YM measurement cut-off value of 4.43 kPa, a value less than or equal to this suggested a no diseased kidney. This yielded sensitivity and specificity of 92.6% and 80.6%, respectively, with an AUROC of 0.92.</p><p><strong>Conclusion: </strong>Our results demonstrated that shear wave elastography may provide a low-cost, non-invasive method for the morphological assessment and progression of the disease status in chronic kidney disease patients with CKD.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"307-317"},"PeriodicalIF":2.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chorea in Hemodialysis Patients: Report of Two Cases. 血液透析患者的舞蹈病:附2例报告。
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-30 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S490816
Xiaoxia Chen, Yafeng Zhang, Yue Zhou

Background: Chorea is rare in maintenance dialysis patients but seriously affects the quality of life, and there are few previous reports of this condition. We report two patients undergoing regular hemodialysis for end-stage renal disease, both of whom presented with progressively intensified involuntary limb movements, but originating from different etiologies.

Case presentation: We report two patients undergoing regular hemodialysis for end-stage renal disease who presented with progressively intensified involuntary limb movements. Treatment with sedatives alone proved ineffective in both cases. Through differential diagnosis, one patient was diagnosed with diabetic striatopathy and managed with intensive glycemic control, while the other was found to have uremic metabolic encephalopathy and treated with a combination of hemodialysis and hemoperfusion. Subsequently the patients' symptoms improved significantly.

Conclusion: Choreiform movements in hemodialysis patients arise from a variety of etiologies. These two cases suggested the susceptibility to the onset of chorea in the early stage of maintenance hemodialysis.

背景:舞蹈病在维持性透析患者中很少见,但严重影响患者的生活质量,以往关于该病的报道很少。我们报告了两例接受定期血液透析治疗终末期肾脏疾病的患者,他们都表现为逐渐加剧的不自主肢体运动,但起源于不同的病因。病例介绍:我们报告了两例接受定期血液透析治疗的终末期肾脏疾病患者,他们表现为逐渐加剧的不自主肢体运动。在这两种情况下,单独使用镇静剂治疗被证明无效。通过鉴别诊断,1例患者诊断为糖尿病纹状体病,并进行强化血糖控制,另1例患者诊断为尿毒症代谢性脑病,并联合血液透析和血液灌流治疗。随后患者症状明显改善。结论:血液透析患者的舞蹈样运动由多种病因引起。这两个病例提示维持性血液透析早期易发生舞蹈病。
{"title":"Chorea in Hemodialysis Patients: Report of Two Cases.","authors":"Xiaoxia Chen, Yafeng Zhang, Yue Zhou","doi":"10.2147/IJNRD.S490816","DOIUrl":"10.2147/IJNRD.S490816","url":null,"abstract":"<p><strong>Background: </strong>Chorea is rare in maintenance dialysis patients but seriously affects the quality of life, and there are few previous reports of this condition. We report two patients undergoing regular hemodialysis for end-stage renal disease, both of whom presented with progressively intensified involuntary limb movements, but originating from different etiologies.</p><p><strong>Case presentation: </strong>We report two patients undergoing regular hemodialysis for end-stage renal disease who presented with progressively intensified involuntary limb movements. Treatment with sedatives alone proved ineffective in both cases. Through differential diagnosis, one patient was diagnosed with diabetic striatopathy and managed with intensive glycemic control, while the other was found to have uremic metabolic encephalopathy and treated with a combination of hemodialysis and hemoperfusion. Subsequently the patients' symptoms improved significantly.</p><p><strong>Conclusion: </strong>Choreiform movements in hemodialysis patients arise from a variety of etiologies. These two cases suggested the susceptibility to the onset of chorea in the early stage of maintenance hemodialysis.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"301-306"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associated Factors for Chronic Kidney Disease in Patients with Diabetes Mellitus 2: Retrospective Study. 2型糖尿病患者慢性肾脏疾病的相关因素:回顾性研究
IF 2.1 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-27 eCollection Date: 2024-01-01 DOI: 10.2147/IJNRD.S489891
Evelyn Del Socorro Goicochea-Rios, Irma Luz Yupari-Azabache, Nélida Milly Otiniano, Néstor Iván Gómez Goicochea

Introduction: Chronic kidney disease affects the quality of life of people with diabetes mellitus, increases cardiovascular risk, and has high social costs.

Objective: To determine associated factors for chronic kidney disease in people with diabetes mellitus type 2.

Material and methods: Retrospective cohort study with 371 patients evaluated in primary care for diabetes mellitus. Information on age, sex, disease duration, comorbidity and laboratory results was obtained. Patients of both sexes attended between 2022 and 2024 were included. Patients with other renal diseases or referrals were excluded. Logistic regression analysis was performed to identify associated factors.

Results: Males (p = 0.014), age >60 years, (p = 0.01) uncontrolled diabetes (HbA1C >7.99%±1.84) and disease duration over 20 years (p = 0.02) are associated factors for chronic kidney disease (CKD). HbA1c had significant differences between those with and those without CKD. The most frequent comorbidities are arterial hypertension (70%), dyslipidemia (43%), overweight/obesity (44%) and anemia (31%). CKD stage G2 is the most frequent (45%). One hundred percent of patients in G1 and G2 CKD stages have an elevated microalbuminuria/creatinuria rate, and 13% of patients between G3a and G4 stages have this rate within normal values. Most patients receive nephroprotection with ARA II and ACEIs.

Conclusion: It is important to screen for kidney disease in patients with diabetes mellitus type 2 who are male, over 60 years of age, with uncontrolled HbA1c and prolonged disease duration, as well as to treat comorbidities and nephroprotection regardless of the stage of chronic kidney disease.

慢性肾脏疾病影响糖尿病患者的生活质量,增加心血管风险,具有很高的社会成本。目的:探讨2型糖尿病合并慢性肾脏疾病的相关因素。材料与方法:对371例糖尿病患者进行回顾性队列研究。获得了有关年龄、性别、病程、合并症和实验室结果的信息。包括2022年至2024年间就诊的男女患者。排除其他肾脏疾病患者或转诊患者。进行Logistic回归分析以确定相关因素。结果:男性(p = 0.014)、年龄bbb60岁(p = 0.01)、未控制糖尿病(HbA1C >7.99%±1.84)和病程超过20年(p = 0.02)是慢性肾脏疾病(CKD)的相关因素。HbA1c在CKD患者和非CKD患者之间有显著差异。最常见的合并症是动脉高血压(70%)、血脂异常(43%)、超重/肥胖(44%)和贫血(31%)。CKD G2期最常见(45%)。100%的G1期和G2期CKD患者微量白蛋白尿/肌酐尿率升高,13%的G3a期和G4期患者该比率在正常值范围内。大多数患者接受ARA II和acei的肾保护。结论:对于男性、60岁以上、HbA1c不受控制、病程延长的2型糖尿病患者进行肾脏疾病筛查、治疗合并症和肾保护具有重要意义,无论慢性肾脏疾病的分期如何。
{"title":"Associated Factors for Chronic Kidney Disease in Patients with Diabetes Mellitus 2: Retrospective Study.","authors":"Evelyn Del Socorro Goicochea-Rios, Irma Luz Yupari-Azabache, Nélida Milly Otiniano, Néstor Iván Gómez Goicochea","doi":"10.2147/IJNRD.S489891","DOIUrl":"https://doi.org/10.2147/IJNRD.S489891","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease affects the quality of life of people with diabetes mellitus, increases cardiovascular risk, and has high social costs.</p><p><strong>Objective: </strong>To determine associated factors for chronic kidney disease in people with diabetes mellitus type 2.</p><p><strong>Material and methods: </strong>Retrospective cohort study with 371 patients evaluated in primary care for diabetes mellitus. Information on age, sex, disease duration, comorbidity and laboratory results was obtained. Patients of both sexes attended between 2022 and 2024 were included. Patients with other renal diseases or referrals were excluded. Logistic regression analysis was performed to identify associated factors.</p><p><strong>Results: </strong>Males (p = 0.014), age >60 years, (p = 0.01) uncontrolled diabetes (HbA1C >7.99%±1.84) and disease duration over 20 years (p = 0.02) are associated factors for chronic kidney disease (CKD). HbA1c had significant differences between those with and those without CKD. The most frequent comorbidities are arterial hypertension (70%), dyslipidemia (43%), overweight/obesity (44%) and anemia (31%). CKD stage G2 is the most frequent (45%). One hundred percent of patients in G1 and G2 CKD stages have an elevated microalbuminuria/creatinuria rate, and 13% of patients between G3a and G4 stages have this rate within normal values. Most patients receive nephroprotection with ARA II and ACEIs.</p><p><strong>Conclusion: </strong>It is important to screen for kidney disease in patients with diabetes mellitus type 2 who are male, over 60 years of age, with uncontrolled HbA1c and prolonged disease duration, as well as to treat comorbidities and nephroprotection regardless of the stage of chronic kidney disease.</p>","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"17 ","pages":"289-300"},"PeriodicalIF":2.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Nephrology and Renovascular Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1